For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.
Combining the anti-PD-1 antibody sintilimab with a pemetrexed-platinum chemotherapy regimen improved survival outcomes in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), interim analysis of the phase III ORIENT-11* trial from China showed.
In patients with locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC), treatment with the ALK tyrosine kinase inhibitor ensartinib led to superior progression-free survival (PFS) compared with crizotinib, according to interim results of the phase III eXalt3* trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.